PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
- 1 December 1999
- journal article
- review article
- Published by Elsevier BV in Hematology/Oncology Clinics of North America
- Vol. 13 (6), 1295-1314
- https://doi.org/10.1016/s0889-8588(05)70128-3
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- Major role of the soluble interleukin‐6/interleukin‐6 receptor complex for the proliferation of interleukin‐6‐dependent human myeloma cell linesEuropean Journal of Immunology, 1997
- Multiple MyelomaNew England Journal of Medicine, 1997
- Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myelomaCancer, 1997
- New perspectives in clinical oncology from angiogenesis researchEuropean Journal Of Cancer, 1996
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parametersAnnals of Hematology, 1991
- Markers of Multiple Hematopoietic-Cell Lineages in Multiple MyelomaNew England Journal of Medicine, 1990
- Serum beta-2-microglobulin binding activity in monoclonal gammopathy: Correlative study and clinical significanceEuropean Journal of Cancer and Clinical Oncology, 1983
- Long-Term Survival in Multiple MyelomaNew England Journal of Medicine, 1983
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971